Nicholas A. Saccomano's Insider Trades & SAST Disclosures
Nicholas A. Saccomano's most recent trade in OnKure Therapeutics Inc. - Ordinary Shares - Class A was a trade of 516 Class A Common Stock done at an average price of $2.7 . Disclosure was reported to the exchange on April 4, 2025.
Add Superstar Alert
Share
Note
This is a custom search result for pattern Nicholas A. Saccomano.To see full superstar portfolios of large investors like Warren Buffet, Elon Musk and others, click here.
Advanced/Help
"Balanced Fund": Use this format with quotation marks to find the exact phrase. The output matches
"Balanced Fund"
but not "Balanced Growth Fund"
Balanced Fund: Use this format without quotation marks to search for all funds related to the term
"Balanced Fund" The results may include
"Balanced Income Fund", "Balanced Growth Fund" and any fund name containing "Balanced Fund".
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| OnKure Therapeutics Inc. -... | Nicholas A. Saccomano | Director, President and CEO | Sale of securities on an exchange or to another person at price $ 2.67 per share. | 04 Apr 2025 | 516 | 3,682 | - | 2.7 | 1,378 | Class A Common Stock |
| OnKure Therapeutics Inc. -... | Nicholas A. Saccomano | Director, President and CEO | Sale of securities on an exchange or to another person at price $ 3.33 per share. | 04 Apr 2025 | 358 | 4,198 | - | 3.3 | 1,191 | Class A Common Stock |
| OnKure Therapeutics Inc. -... | Nicholas A. Saccomano | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 27 Jan 2025 | 130,000 | 130,000 | - | - | Employee Stock Option (right to buy) | |
| OnKure Therapeutics Inc. -... | Nicholas A. Saccomano | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 Oct 2024 | 542,232 | 542,232 | - | - | Employee Stock Option (right to buy) | |
| OnKure Therapeutics Inc. -... | Nicholas A. Saccomano | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 Oct 2024 | 16,898 | 16,898 | - | - | Employee Stock Option (right to buy) | |
| OnKure Therapeutics Inc. -... | Nicholas A. Saccomano | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 Oct 2024 | 8,449 | 8,449 | - | - | Employee Stock Option (right to buy) | |
| OnKure Therapeutics Inc. -... | Nicholas A. Saccomano | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 Oct 2024 | 4,556 | 4,556 | - | - | Class A Common Stock | |
| OnKure Therapeutics Inc. -... | Nicholas A. Saccomano | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 Oct 2024 | 2,359 | 2,359 | - | - | Employee Stock Option (right to buy) | |
| OnKure Therapeutics Inc. -... | Nicholas A. Saccomano | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 Oct 2024 | 1,485 | 1,485 | - | - | Employee Stock Option (right to buy) |
*All Values are in $ Million
Client Category: Promoter/ KMP/ Director / Immediate Relatives / Employee / etc
Security Type: Share/ Warrants / Convertible Debentures
Security Type: Share/ Warrants / Convertible Debentures
Data as reported to USA Exchanges